
The American Society of Human Genetics Annual Meeting (ASHG 2025) opened on Tuesday, October 14, with welcoming remarks by ASHG CEO Amanda Perl and her introduction of ASHG President Sarah Tishkoff, PhD, who gave the Presidential Address titled “Stronger Together: Advancing Human Genetics Through the Power of Community.” After her address, Tishkoff introduced the legendary Francis Collins, MD, PhD, for special recognition.
Roller-Coaster Year & ASHG As Home
Dr. Tishkoff began her talk by thanking the ASHG staff for its fantastic work through what she described as a roller-coaster year. “Serving as president of the ASHG has truly been one of the greatest honors of my career,” she said. She described her first ASHG meeting which she attended as a graduate student and said “I still remember that. I was excited; I was overwhelmed; I was a bit intimidated, but I also remember feeling at home. This community has always been a place where I can catch up with colleagues, spark new collaborations, and be inspired by the latest research in the field. So, to the trainees out there today, if you had told me back then that one day I was going to be president of the ASHG, I would have said ‘You’re out of your mind.’ So, my advice to you is simple. Follow your passions, seize opportunities when you can volunteer to participate on an ASHG committee, and if at first you don’t succeed, keep trying. I really can’t wait to see one of you on the stage in the future, leading on the Board.”
Women in ASHG Leadership & Global Membership
“I am also especially honored to be the 14th woman president of the ASHG in the 77-year history of our society. In fact, the past president, the new president, and the president-elect are all women and the entire executive board, for the first time will be composed entirely of women.
“We still have progress to make, to ensure that leadership truly reflects all member of our global community. Why does this matter? Well, because when leadership does not reflect the various backgrounds, experiences, and perspectives of the broader community, it can fuel self-doubt and we miss out on the valuable insights that members of various backgrounds bring.”
Challenges & Devastating Impact
“Unfortunately, initiatives to increases diversity in the biomedical workforce have been challenged this year. Indeed, science itself has recently been under attack. We’ve witnessed the abrupt termination of thousands of scientists and staff at the NIH and the CDC. We’ve heard from so many of you who have been directly impacted by recent policy shifts. Many of you have had your research funding withheld or abruptly canceled. Many NIH institutes now require to commit funding for all years rather than just one year at a time as was usually done, making 2025 the most challenging year to get a grant that I can personally remember. Because of the massive grant cancellations and delays, hundreds of staff were laid off at many research institutions. Graduate programs have drastically cut back on the number of students they can accept and faculty hiring has been paused.”
“All of this could have a devastating impact on the next generation of scientists in the United States, and in addition international collaborations were abruptly cancelled. Visas for international students and post-docs are critically important for research and were threatened in the US and elsewhere.”
“These attacks on science are not just devastating they are traumatizing. The challenges threaten not just individual labs, but the very foundation of our global leadership in science. And that is why I am so proud of the work the ASHG has done in regard to advocacy. I have been to the Capitol a few times and have also gone with other members the Advocacy Committee.”
Advocacy Efforts
“The Advocates’ tireless efforts ensure that our voices are heard on Capitol Hill, highlighting to Congress that robust NIH funding is vital for attracting top talent from the US and abroad, maintaining US leadership in in biomedical research, strengthening local and national economies, and most importantly advancing the diagnostics and treatments that improve human health.”
“So, while there’s currently a government shutdown, and we very much miss our NIH and other agency colleagues who are unable to be here this week, we did have some early indications that ASHG advocacy efforts were paying off. Before the shutdown, we saw bipartisan support to keep NIH funding either stable or slightly increased as part of the 2026 appropriations bill. I really hope there will soon be a resolution to the government shutdown and that a momentum is maintained for keeping biomedical research at a high-enough level to sustain it.”
“I also want to thank all of you here who took the time to talk to your local representative. It really has made a difference.” Dr. Tishkoff then called for a round of applause for all those ASHG members who had lobbied their representatives.
Much Work Ahead
“There is still more work ahead, she continued. “Research funding remains under threat. The process for future grant decisions is still uncertain. Even though there is a shutdown now, I still want to encourage everyone to continue to reach out to your local representative and communicate the importance of ending the impasse, opening the government, funding the NIH at levels needed to sustain biomedical research and keep the science going. It’s absolutely essential that we keep this outreach going. Congressional staff say that letters and calls really do make a difference. Tell them how the shutdown and funding cuts personally affect you. The representative really like to hear stories, particularly stories on health.”
She noted that attendees could visit the NIH booth, where they can pick up postcards that tell you exactly how to contact your representative. “Let’s keep the momentum going,” she said.
ASHG Stands Firm in Its Global Commitment
“Despite the many challenges of this year, the ASHG has stood firm in its values and its vision that people everywhere realize the benefits of human genetics and genomics research. So, this means having members who reflect the broader global community, and advocating for research that includes participants across all backgrounds. Human genetics and genomics research must be global and inclusive to thrive. To truly understand human biology, health, and disease we must study populations from diverse ancestries, environments, and regions of the world.”
Dr. Tishkoff on Science
Next came Dr. Tishkoff’s favorite part which is the scientific portion of her presentation. She spoke about what some of the evolutionary forces are that result in the patterns of variation that we see today and how those might impact both health and disease. Her research focuses on studying genomic and phenotypic variation in Africa. Her discussion focused first on the classic example of sickle cell disease and malaria and also on the APOL1 gene for which two variants are associated with a 7- to 20-fold greater risk of a chronic kidney disease. The same two APOL1 variants are protective against a parasite that causes sleeping sickness.
Dr. Tishkofff said another motivation in her research is understanding risk factors for health disparities. For example, hypertension is more common in those of African ancestry in the US, and adult-onset diabetes is more common in those of native American ancestry and African Americans compared to other ancestries. A key problem is distinguishing between environmental versus genetic factors in these disparities. There’s a major bias in genetic studies toward those of European ancestry. This is a problem for a number of reasons, including the fact that results obtained in a European-based study may not be applicable to those of different ancestries.
She noted a classic study by Helen Hobbs and colleagues in which they identified nonsense mutations in the PCSK9 gene that are associated with lower LDL. These mutations were only found in people of African ancestry. They would not have been found in studies of other populations. That important discovery identified PCSK9 as a potential drug target and led to the development of a therapeutic that was effective in lowering LDL levels in people of all populations.
“I also wanted to point out that many of the discoveries I’ve highlighted would not have been possible without international collaborations. International collaboration isn’t optional; it’s essential. It fuels larger more powerful studies, it fosters innovation, and it ensures that discoveries benefit people everywhere.”
Amazing Recent Work
Dr. Tishkoff ended her scientific discussion by highlighting some of the amazing work that has been done recently in curing or treating genetic diseases with gene therapy. The first sickle cell gene therapies were approved by the FDA in 2023. One uses a CRISPR-based editing approach, while the other uses a lenti virus to introduce a functional copy of the beta-globin gene. “These are remarkable but very invasive procedures costing millions of dollars for each treatment. Under 200 people have received this so far. We need to develop more affordable treatments.”
“Lastly, I would like to highlight the development this year of the first personalized CRISPR-based gene therapy to treat an ultra-rare and deadly disorder in a baby using an infusion-based approach. This is really a remarkable achievement.”
ASHG Global Community Is Home
“I’d like to end by highlighting that ASHG feels like home to so many of us because it unites us across disciplines, borders, and career stages to advance a shared vision. The society is more than a professional association, it is a global hub where the future of genetics and genomics takes shape.”
“Finally, in light of the multiple and important roles that ASHG play, we made a bold and meaningful decision this year to significantly increase the amount of funding for our travel grants from $30,000 to more than $75,000. This was not just a budget-line item; it was a response to a clear need. We knew that access to our annual meeting, to collaboration, to mentorship, and the scientific exchange shouldn’t be limited by geography or financial barriers. That’s what community looks like and that’s what the future of genetics looks like—inclusive, connected, and driven by opportunity.”
Standing Together
“As we begin this meeting, I invite you to immerse yourself in the science, connect with colleagues—old and new—and remember that this society is strongest when we stand together. In moments of challenge like we’re facing now, we find resilience in each other. And in moments of discovery, we move the world forward together. Thank you so much for the honor of serving as your president. I can’t wait to see all that we will achieve in Boston this week and in the years to come.”
Introduction of Dr. Francis Collins
At the end of her remarks, Dr. Tishkoff introduced Dr. Francis Collins for very special recognition by the ASHG. “It is a true privilege to honor Dr. Francis Collins whose contributions to genetics and biomedical research have been profound and enduring. His efforts as one of the architects and leaders of the human genome project helped unlock the blueprint of human life and advanced medicine and genetic discovery. His earlier work on the genetics of cystic fibrosis, neurofibromatosis, and Huntington’s disease laid the foundation for countless advances in diagnosis and treatment. During his time as director of the National Human Genome Research Institute (NHGRI) and later as director of the NIH, Dr. Collins championed bold initiatives from the All of Us Research Program to COVID-19 vaccine development, while consistently advocating for ethical standards, data privacy, and equitable access to genomic medicine.”
“Dr. Collins has also been a long-time supporter and contributor to the ASHG community inspiring generations of geneticists with his scientific rigor, his humility and unwavering commitment to improving human health. He is the recipient of both the ASHG lifetime achievement award and leadership award. He has been an active participant and symposium speaker at past ASHG meetings. His legacy isn’t just in the science he’s advanced, it’s in the cooperative spirit and ethical compass he’s brought to the field.”
With a picture of Dr. Collins playing the guitar shown on the screen, Dr. Tishkoff urged the audience not to forget Dr. Collins’ musical side, which had happily entertained participants at the ASHG’s 75th anniversary gala.
“On behalf of the ASHG and the broader genetics community, we extend our deepest gratitude to Dr. Collins for his leadership, vision, and lasting contributions to science and society.”
With that, Dr. Tishkoff called Dr. Collins, sans guitar, to the stage for special recognition and to say a few words to the thousands who had come to honor him.
Dr. Francis Collins
After a thunderous and sustained standing ovation, Dr. Collins greeted his myriad admirers. “Wow, my family—it’s so good to be here with you,” he said with a broad smile. “This is my 48th meeting of the American Society of Human Genetics.” His first ASHG meeting was in 1978 and was only attended by a few hundred people but at least two presentations documented key advances and Dr. Collins suggested that perhaps those attending this meeting for the first time might also come away with new insights leading to future breakthroughs. He noted that “we are well on the way now with Mendelian disorders, but common diseases with GWAS—yeah, they got pretty complicated didn’t they?” he said. “Something like 627 genes are now associated with type 2 diabetes, while we thought there might only be a dozen or so when we started. But that is the way it is. Really challenging and really interesting.”
“We Are All Africans”
Dr. Collins emphasized the importance of Dr. Tishkoff’s admonition on the necessity of circling the globe in genetic studies, the importance of cataloging variation across multiple populations, especially in Africa. “We are all Africans,” Dr. Collins said, “and we should put every bit of energy we can into trying to see what we can learn from that excellent store of genetic variation. And I’m proud to be part of an effort now to try to build a new Centers of Excellence program for genomics across the continent of Africa that can build on the work that was already done through the H3 program and take it to the next level.”
“To come up with treatments, may I say even cures. I’m glad that Sarah has already talked about sickle cell. Now, my former lab is within a year, of approaching what we may have an in vivo gene editing treatment for progeria (disease of accelerated aging). Never could I have imagined this occurring in the course of my career. We’re on a roll here in terms of progress of science in terms of nothing that was thought possible before.”
Difficult Times
“But we’re also in a very difficult time. And Sarah spoke very effectively about just how serious that is and maybe what our response should be. Since January at NIH 2,500 scientists have been let go, mostly without explanation. I was made terminally unwelcome myself on February 28 of this year so I now stand before you as an unemployed person. And, of course, the same kind of things were done to our colleagues at NSF and CDC and FDA really hobbling our government’s ability to move forward all these exciting advances that we’re here to talk about at this meeting. 2,500 grants were terminated–the explanation or excuse initially was that it’s all about DEI. There was a big spillover from that into things that were really health disparities that ought to be of very high priority for our country and the world to try to understand. And, of course, it also captured much of HIV research which got severely harmed.”
Truth Itself Under Attack
“And there were other odd things—like you’re not allowed to do a grant that studies vaccine hesitancy. That’s no longer allowed. And global health got caught up in this in a very unfortunate way and piling on top of this was highly serious harm that was done by the dismantling of USAID. NIH investments in global health, while not stopped, became extremely complicated to pursue and certainly slowed down a lot of things that were in a pretty interesting place. Academic institutions are under stress, some of them quite severely, with dollars that are simply not coming and people struggling to keep projects going. In some instances, it may be the whole institution that takes that particular harm onboard and we end up stopping things like cancer research and Alzheimer’s research and even clinical trials. Truth itself is under attack. You see them–young scientists are wondering in this country what is the future going to be like if this is the path we are on. We owe it to do everything we can to encourage those folks that we’re going to get through this.”
“I have to also mention my colleagues at NIH who were planning to be here, planning to present their work, their posters, people in my former lab—they’re all at home because the government shut down for the 14th day.”
Tell Your Story to Your Representative
“So, what can we do about this? This is the question I get asked—what can we do You already heard a lot from Sarah. Take those recommendations, fill out those postcards and, at a minimum, make those calls (to government representatives), But more importantly I would love to have more of you reach out to your elected representative in Congress and invite them to your lab or your clinic –to let them see what you do and why you are so excited about it.”
“When I was NIH director that was the single most important moment–bringing a member of Congress to say, ‘hey this matters, this is going to be a priority for me.’ We don’t do that nearly enough. Yes, make an appointment with your congressman and tell your story. Tell it personally.”
